**ABSTRACT**

Migraine is a type of primary headache disorder that can become chronic and disabling. The exact pathomechanism of migraine is not known very well and its treatment is also difficult in some cases. There are several medications for the acute and preventive treatment of migraine including the “triptan” family drugs, nonsteroidal anti-inflammatory drugs, anti-epileptic drugs, beta-blockers, and Ca\(^{2+}\)-channel blockers\(^1\) and those against calcitonin gene-related peptide or its receptor that are reviewed elsewhere.\(^2\) However, there are some medically intractable headaches or patient management is unsatisfactory or medications are poorly tolerated\(^3\) or there are contraindications. Therefore, neuromodulation and nerve stimulation methods that have proven effective in clinical research may provide an additional treatment option for acute and preventive treatment of migraine. In this brief review, we will discuss recent advances using neuromodulatory techniques that are currently used in the treatment of headaches in clinical studies. These include the electrical stimulation of occipital nerve, sphenopalatine ganglion, supraorbital nerve, and transcutaneous electrical stimulation of vagus nerve as well as single-pulse transcranial magnetic stimulation. Several clinical studies have conducted neurostimulation for the acute and preventive treatment of migraine in recent years but more studies are necessary to see their efficacy and long-term effect.

**KEYWORDS:** Neuromodulation; Migraine treatment; Nerve stimulation.

**ABBREVIATIONS:**
- AED: Anti-epileptic drugs
- CGRP: Calcitonin gene-related peptide
- CNS: Central Nervous System
- CM: Chronic Migraine
- fMRI: Functional Magnetic Resonance Imaging
- GABA: Gamma amino butyric acid
- HFEM: High Frequency Episodic Migraine
- mAbs: Monoclonal antibodies
- NSAIDS: Nonsteroidal anti-inflammatory drugs
- nVNS: Non-invasive vagal nerve stimulation
- ONS: Occipital Nerve Stimulation
- PET: Positron Emission Tomography
- SoC: Standard of Care
- SPMG: Sphenopalatine ganglion
- TMS: Transcranial Magnetic Stimulation
- TESoSN: Transcutaneous electrical stimulation of supraorbital nerve
- VNS: Vagus/Vagal Nerve Stimulation

**INTRODUCTION**

Migraine is a disabling brain disorder that is believed to be due to the dysfunction of the subcortical structures including diencephalic and brain stem areas that are involved in the processing and modulation of painful stimuli, leading to a dysmodulation of pain and vascular tone especially in the trigeminovascular system of susceptible patients.\(^4\) There are two types of migraine: Migraine without aura and migraine with aura that occurs in about 30% of the migraine patients.\(^9\) Activation of cortical neurons, the cortical spreading depression of Leão has long been proposed for the pathophysiology of migraine with aura \(^10,11\) and a number of genetic abnormalities (channelopathies) have been detected in migraine patients with aura.\(^12-17\) Migraine is a disabling disorder characterized by a unilateral pulsatile headache that is often accompanied by nausea and vomiting and lasts for 4-72 hours.\(^18\) Migraine is a multifactorial disorder that is more common in females and is sometimes associated with comorbid disorders such as depression and epilepsy.\(^19\) Genome-wide association studies have shown 13 migraine-associated variants that are involved in synaptic function, glutamatergic neurotransmission, nociception,
Migraine can be episodic (frequency of attacks <15 days per month) or become chronic when frequency of the attacks is >15 days per month, 8 days of which have migraine features and the condition lasts more than 3 month. Classification of different headache disorders has been continuously updated to better facilitate the diagnosis and treatment of headache. The third edition (beta version) of the International Classification of Headache Disorders is an updated source for classification of headache disorders. The exact pathomechanism of migraine is not known and its treatment remains challenging. Some of the main drugs that are currently being used in the acute and preventive treatment of migraine include the “triptans” and nonsteroidal anti-inflammatory drugs (NSAIDS), anti-epileptic drugs (AED), beta-blockers, and Ca²⁺-channel blockers among others. Several neurotransmitters and neuromodulators have been implicated in the pathomechanism of migraine. Among those, calcitonin gene-related peptide (CGRP) is one of the few neuropeptides that has been implicated in the pathogenesis of migraine and its increased level has been detected in the blood of migraine patients with and without aura. Therefore, some more specific newer drugs such CGRP-receptor antagonists, known as “gepants” family of drugs such as Olcegepant or Telcagepant, and MK-3207, BI 44370 TA, BMS-846372 and a few others in this category were developed in recent years but were discontinued in their clinical trials phase II and III or at an earlier stage mainly because of their liver toxicity and other problems. A recent double-blind, placebo-controlled, phase II b clinical trial randomized 834 participants to treat one migraine attack with various doses of Ubrogepant (MK-1602). In that study, 527 participants received the drug and 113 received placebo. Their result shows that 100 mg ubrogepant was significantly superior to the placebo for causing 2-hour pain-free (25.5% versus 8.9%) but not for 2-hour headache response. According to that study, this CGRP-receptor antagonist geapa family drug is effective in treating migraine and the adverse events among the ubrogepant and placebo treated patients are similar; therefore, their results seem promising.

In recent years, newer (migraine-specific) drugs were developed. These include the 3 monoclonal antibodies (mAbs) against CGRP with long-term effects, the LY2951742, the ALD-403, and TEV-48125 (LBR-101) and AMG 334, a mAb against CGRP receptor complex that has been developed by Amgen have shown efficacy and tolerability in clinical trials with some minor side effects but are still under examination in clinical trials.

A few other drugs including one acting on 5-HT₄ receptor such as Lasmiditan (COL 144) in phase II and III studies (that seem promising) and drugs targeting nitric oxide synthase, glutamate, acid-sensing ion channels, or gamma amino butyric acid (GABA)-A are still under investigation, please see references for comprehensive review of the current treatment of migraine.

In spite of several medications available for the prevention and treatment of migraine, invasive and non-invasive approaches such as peripheral nerve blocks, botulinum toxin injection and electrical stimulation of various nerves have gained some focus in the treatment of chronic migraine in recent years. There are a number of patients with medically intractable headache syndromes or chronic migraine that are non-responders to medications or poorly tolerate pharmacological medications or have contraindications and may need an alternative therapy. Therefore, in recent years, neuromodulation and neurostimulation has been examined in a number of clinical studies to test their efficacy and tolerability as a novel method for the acute and preventive treatment of migraine.

This is a brief review of new advances and our current understanding of some invasive (greater occipital nerve or sphenopalatine ganglion stimulation) and non-invasive (transcutaneous vagal or supraorbital nerve stimulation or single-pulse transcranial magnetic stimulation) approaches implicated in the treatment of migraine.

The invasive devices are implanted subcutaneously or through other surgeries and the non-invasive devices are applied on the skin close the nerve and are self-administered by the patient. The results of some of these non-medication approaches are promising but more studies and data are needed to understand their efficacy and tolerability and long-term effects and side effects.

**ELECTRICAL STIMULATION OF OCCIPITAL NERVE**

Electrical stimulation of peripheral nerves for a long-term pain relief in human has been used through implantation of stimulator devices in the body in several clinical investigations for some decade now.

Some of the mechanisms by which electrical stimulation relieves pain seems to be driven from the well-known “gate theory of pain” and modulation of neurotransmitters release including neuropeptides and GABA-ergic system in the central nervous system.

Electrical stimulation of superior sagittal sinus in cat increased activity in the caudal trigeminal nucleus, the cervical dorsal horn and in the dorsolateral spinal cord at the C2 level showing a convergence of neuroanatomical substrates of head pain on the second order neurons of trigeminocervical system.

Electrical stimulation of the occipital nerve has shown effectiveness in treating the intractable pain of occipital neuralgias that were refractory to other medications.

One of the first multicenter, randomized, blinded studies for preventive treatment of chronic migraine, the ONSTIM feasibility study, used occipital nerve stimulation (ONS) by means of implantation of a pulse generator device subcutane-
ously superficial to the fascia and muscle layer at the C1 level. The study assigned 75 out of 110 eligible patients to a treatment group. Their criteria for a responder was a patient who achieved a 50% or more reduction in the number of pain headache days per month or a three-point or more decrease in average overall pain intensity when compared to baseline. That study showed 39% 3-month responders in adjustable stimulation group while the group with preset stimulation or medical management (the control groups) had 6% and 0% 3-month responder rates raising hope for ONS as a treatment option for some chronic migraine patients.

The other large-scale, multicenter, clinical study using ONS was conducted on 105 chronic migraine patients with active stimulation and 52 with sham-stimulation. The neurostimulation device was implanted near the occipital nerves. The criteria for responders were those patients that achieved ≥50% reduction in mean daily visual analog scale scores by 12 weeks following the procedure. The study did not meet their own primary endpoint pain criteria and there was not a significant difference in the percentage of responders in the active stimulated group compared with the sham stimulated group. However, there was a significant difference in the percentage of patients that achieved 30% pain reduction. There was also a significant decrease in headache days, and migraine associated disabilities between the active stimulated versus the sham stimulated group. Some other ONS studies did not show a significant difference between the stimulated versus sham stimulated groups.

Similarly, a recent study on 53 patients with chronic migraine (CM) and some with other associated chronic headache phenotypes in addition to CM had similar result; ONS was delivered through implanted device in a single center between 2007 and 2013. Following an average of 42-month follow-up, there was a 45.3% response rate in the whole cohort defined as ≥30% reduction in moderate to severe headache days per month, that is 34.3% in the CM group alone and 66.7% in those with multiple headache syndromes. They also noticed significant reduction in the intensity and duration of pain as well as headache-associated disabilities. The overall mean subjective patient estimate of improvement was 31.7%.

Therefore, although there are some success reports in ONS, at the moment the results are diverse and more studies are necessary to see the efficacy of ONS in the prevention of migraine. More studies using advanced technology in nerve stimulation might have different outcomes as a new study shows better efficacy of burst ONS compared to tonic stimulation in treating animals with trigeminal allodynia.

Consistent with these, customization of stimulation parameters is important in the result of such interventions as suprathreshold stimulation was found to yield better results in the treatment of migraine although subthreshold stimulation was also helpful.

SPHENOPALATINE GANGLION STIMULATION

Sphenopalatine ganglion (SPG) is the largest extracranial parasympathetic ganglion involved in the innervation of meninges, lacrimal gland, nasal mucosa and conjunctiva that all have been implicated in migraine with autonomic cephalic symptoms including lacrimation, nasal congestion and conjunctival injection in common migraine patients. The postsynaptic projections of the SPG supply lacrimal and nasal glands and are involved in several pain syndromes including trigeminal and sphenopalatine neuralgias, atypical facial pain and headache. Therefore, blocking SPG has been used to treat atypical facial pain. Involvement of SPG in neurovascular headache has been proposed since early 1900.

Electrical stimulation of SPG has been also performed for determination of cerebral blood flow and glucose metabolism.

Two mechanisms of action have been proposed for the role of electrical stimulation of SPG in relieving pain. These include possibly the interruption of post-ganglionic parasympathetic outflow, and modulation of sensory processing in the caudal trigeminal nucleus.

A clinical investigation using electrical stimulation of SPG for ≤60 minutes in 11 medically refractory migraine patients (one patient was not stimulated) alleviated the pain in only half of the patients although the failure was attributed to technical problems. The SPG was accessed by a 20-gauge needle through infrrazygomatic transcoronoid approach into the sphenopalatine fossa visualized under fluoroscopy; a unilateral electrical stimulation of the SPG was delivered by a Medtronic 3057 test stimulation lead following induction of migraine. Stimulating parameters in that study were the following: Mean amplitude: 1.2 V, mean pulse rate: 67 Hz, and mean pulse width: 462 microseconds. Although the failure was attributed to technical problems, the SPG was accessed by a 20-gauge needle through infrrazygomatic transcoronoid approach into the sphenopalatine fossa visualized under fluoroscopy; a unilateral electrical stimulation of the SPG was delivered by a Medtronic 3057 test stimulation lead following induction of migraine.

Clinical trials (NCT01540799, and NCT02510742, https://clinicaltrials.gov) with electrical stimulation of SPG in migraine patients might shed light into our understanding on the role of such procedures in treatment of migraine. Current data is insufficient and more clinical studies are needed to understand the efficacy, tolerability, convenience, and long-term effect of SPG stimulation in the acute treatment of migraine. Moreover, molecular and imaging studies following SPG stimulation may shed light into the mechanism of its modulation of pain.

TRANSRECEPTOR ELECTRICAL STIMULATION OF SUPRORBITAL NERVE (TEssoSN)

Transcutaneous electrical stimulation of peripheral nerves in human has long been performed for various pain syndromes that could not be treated otherwise and the outcomes were satisfac-
These non-invasive impulse generator devices are placed on the skin close to the nerves and they transmit the electrical impulses transcutaneously through electrodes to the nerves.

A recent study using transcutaneous electrical stimulation of supraorbital nerve (TESoSN) for 8 weeks in 12 patients suffering from depression and post-traumatic stress disorder (PTSD) in an out-patient open trial resulted in significant improvement of the symptoms.\textsuperscript{69} Available evidence shows some effectiveness of TESoSN in treatment of migraine.\textsuperscript{69}

Using a new stimulator called “Cefaly” (STX-Med, Herstal, Belgium), the supraorbital nerve branch of the trigeminal nerve was stimulated in a double-blinded, randomized, sham-controlled trial in 67 patients for the prevention of migraine in 5 Belgian tertiary headache clinics. The Cefaly headband is placed on the skin close to the supraorbital and supratrochlear branches of the ophthalmic nerve in the forehead and transmits the electrical impulses transcutaneously through a self-adhesive electrode to the nerves.\textsuperscript{69,70,71} Cefaly device has FDA approval.\textsuperscript{71} The stimulator was used daily for 20 min for 3 months. Results showed that the mean migraine days decreased significantly from 6.94 to 4.88 in the verum stimulated group while there was almost no difference in the sham stimulated group.\textsuperscript{69} Primary outcome measures in that study was a change in monthly migraine days and 50% responder rate. Accordingly, the 50% responder rate was significantly higher (38.1%) in verum stimulated versus sham stimulated group (12.1%). Moreover, TESoSN reduced the attack frequency and total headache day but not the severity of the headache.\textsuperscript{70} PET studies show that Cefaly increases the activity of limbic system including orbitofrontal and anterior cingulate cortices.\textsuperscript{71}

Moreover, a recent study in 24 patients with low frequency migraine attack, a brief period of high frequency TESoSN improved multiple migraine severity parameters.\textsuperscript{72}

The safety and tolerability of TESoSN using Cefaly device was studied in a large group (2313 headache sufferers) in general population who rented the device through internet for a 40-day trial period and was found to be safe and well-tolerated by many people (although it did not help some people and they returned the device).\textsuperscript{73}

External trigeminal nerve stimulation in episodic migraine was also effective for at least 3 weeks but more studies with control group were suggested for better conclusion.\textsuperscript{74}

It appears TESoSN as a non-invasive approach has some moderate effects in the acute and preventive treatment of migraine but more clinical studies will shed lights in the efficacy of the method. One set back with the current technology might be its continuous its daily use for several minutes continued for several months to alleviate some of the migraine symptoms.

**ELECTRICAL STIMULATION OF VAGUS NERVE**

Electrical stimulation of vagus nerve has been used to treat intractable epileptic seizures not responding to medication or surgery but there is no clear mechanism for the regulatory effect of vagus nerve stimulation (VNS) in relieving the symptoms.\textsuperscript{75,76}

Blood oxygenation level changes by VNS since it activates (or increase blood flow to) several cortical and subcortical structures.\textsuperscript{77} Such changes are seen in different thalamic nuclei, insular gyrus, postcentral gyrus, parts of temporal and occipital gyri and basal ganglia using functional magnetic resonance imaging (fMRI) or positron emission tomography (PET) studies in human.\textsuperscript{78-80} Brain blood flow increased in rostral and dorsal central medulla, right postcentral gyrus, bilateral thalamus and hypothalamus, insular cortices and lower cerebellum upon left cervical VNS in partial epileptic patients while blood flow decreased bilaterally in hippocampus, amygdala and posterior cingulate gyrus.\textsuperscript{79}

VNS in a few epileptic patients who were also suffering from migraine resulted in improvement of headache.\textsuperscript{81} VNS significantly improved the symptoms in 5 patients with chronic refractory migraine or cluster headache\textsuperscript{82} or in 4 adult female patients with drug-refractory chronic migraine\textsuperscript{83} or in 13 patients with refractory epilepsy and migraine.\textsuperscript{84}

Nevertheless, a small study shows that low intensity VNS in epileptic patients decreased the thermal pain threshold in human subjects.\textsuperscript{85}

Some vagal afferent nerve fibers terminate in the trigeminal nucleus and animal studies show that electrical stimulation of vagus nerve modulates trigeminovascular nociception (see the discussion please). Both invasive and non-invasive VNS has recently been shown to inhibit cortical spreading depression in rat.\textsuperscript{86}

The VNS was delivered on 27 migraine patients with and without aura in an open-label, single arm, multiple attack pilot study and their results indicate the efficacy and tolerability of VNS in episodic migraine patients.\textsuperscript{87}

Up to 4 migraine attacks were treated in that study by VNS with two 90-sec dose at 15-min intervals that were delivered to the right vagus nerve (cervical branch) within a 6-week time period. Patients were allowed to self-treat at moderate or severe pain or following 20-min of a mild pain. The pain was aborted at 2 hours in 22% of patients with moderate or severe attacks at baseline.\textsuperscript{87}

Another more recent open-label, single-arm, multicenter study used VNS on 36 patients with chronic migraine and 14 suffering from high frequency episodic migraine (HFEM).
Patients self-treated up to 3 consecutive mild or moderate migraine attacks occurring in 2-week period by delivery of two 120-second doses on VNS at 3-min intervals to the right vagal nerve (cervical branch). They found that 56.3% of the patients had pain reduction (≥50% reduction in visual analog scale “VAS” score) at 1 hour and 64.6% at 2 hour. Of these patients, 35.4% and 39.6% reached a pain-free (VAS:0) situation at 1 and 2 hours respectively. The pain-relief rate was 38.2% and 51.1% at 1 and 2 hour respectively when all attacks (N=131) were considered and pain-free rates in latter cases were approximately half of the corresponding percentages, indicating that the non-invasive VNS is an effective method for acute treatment of chronic migraine or HFCM.  

Another trial, a monocentric, randomized, controlled, double-blind study in 40 patients with chronic migraine also shows that electrical stimulation of the auricular branch of the vagus nerve by means of a battery driven handhold stimulator to the sensory areas of left ear at 1 Hz for 4 hours per day for 3 months has significantly reduced the pain days (≥50% reduction in headache days) and improved the headache impact test and disability assessment test.  

Non-invasive vagal nerve stimulation (nVNS) in 20 patients with treatment-refractory migraine has also been shown to be effective in the prevention and treatment of episodic and chronic migraine patients with associated sleep disturbances. In that 3-month open-label, prospective observational study, 20 patients with treatment-refractory migraine were treated twice daily with nVNS prophylactically at pre-specified times and acutely as the adjunctive therapy for migraine attacks. Results show significant reduction in frequency, intensity, and duration of pain and improvements in migraine associated disability, depression and quality of sleep in treatment-refractory migraine patients. 

The most recent pilot prospective, multicenter, double-blind, sham-controlled study, the EVENT study, shows also that nVNS is well tolerated and safe but did not significantly change the headache days in chronic migraine patients who had >15 headache days per month. Fifty nine patients took part in this study, 30 patients with nVNS and 29 had sham-treatment. Patients had a 1 month baseline phase and were randomized subsequently to nVNS or sham-treatment for 2 months before receiving open-label nVNS. Mean reduction in the number of headache days was 1.4 in the nVNS versus 0.2 day in the sham-treatment group and the difference was not significant but there was a trend p=0.56 The study concluded that consistent use of nVNS as a prophylactic treatment of chronic migraine can reduce the headache days but larger sham-controlled studies are needed. 

The nVNS has also been effective in prophylactic treatment of cluster headache in PREVA group study. This prospective, open-label, randomized study worked on 48 patients who received adjunctive nVNS plus standard of care (SoC) and 49 control patients only with the SoC alone. The duration and plan of the study comprised of 2-weeks baseline phase followed by 4-weeks randomized phase (nVNS plus SoC versus control group who received only SoC alone) followed by 4-weeks extension phase (nVNS plus SoC). Their results show that the ≥50% response rate was higher (40%) in the nVNS plus SoC group compared to 8.3% in the SoC alone treated control group.  

There are evidences that electrical stimulation of the nerves leads to the release of neurotransmitters or neuromodulators and vasoactive substances from their peripheral and central nerve endings affecting the vascular permeability or tissue inflammatory molecules peripherally and neurotransmission in the CNS. Electrical stimulation of the vagus nerve seems to decrease the severity of rheumatoid arthritis perhaps by inhibition of cytokine production.  

Overall, nVNS seems promising in the acute and preventive treatment of migraine and is suggested to be continued in clinical trials to gather more information about its effectiveness in the treatment of migraine headaches and to understand the mechanism(s) of its effectiveness in trigeminocervical pain. In addition, as discussed above, blood oxygenation level and metabolic activities of a number of brain regions increase or decrease following VNS. Therefore, more basic research in VNS may add more knowledge to our current understanding of the brain central pain modulatory centers. 

TRANSCRANIAL MAGNETIC STIMULATION  

Transcranial magnetic stimulation (TMS) is a method that has been used to activate the motor cortex and study the facial motor responses or elsewhere in the body but it also seems to alleviate the pain of migraine patient with aura.  

Transcranial stimulation is based on electromagnetic technology. A pulse of current passes through a coil that is located in a portable device which can be placed on the individual’s head (i.e. in the occipital region) for a short time and when turned on, it depolarizes neurons in the target area. 

A randomized, double-blind, parallel-group, two phase, sham-controlled study in 18 centers in the United States investigated the pain relief in 267 adults suffering from migraine with aura, of which 66 patients were dropped in phase one. The remaining 201 patients were randomly chosen to have the single-pulse transcranial magnetic stimulation (sTMS, n=102) or sham-stimulation (n=99). The patients were informed to treat up to 3 attacks over 3 months when experience aura. Out of 201 patients, 37 who didn’t treat a migraine attack were excluded and the rest were divided equally into the sTMS or sham stimulated groups (n=82 for each group). The pain-free response after 2 hours was 39% in the sTMS group compared to 22% in the sham stimulated group. Pain free status at 24 hours and 48 hours post-treatment was still significantly higher in the TMS group but other symptoms such as nausea, photophobia and phonophobia...
Migraine is one of the most prevalent neurological disorders that is characterized by headache, gastrointestinal problems and sensory dysfunction. Because of its multifactorial etiology, migraine is very difficult to treat. Migraine therapy is based on the acute and preventive treatment. There are several pharmacological and non-pharmacological treatments of migraine currently available in clinical practice. Many of the pharmacologic treatment of migraine have side effects and contraindications and with the insufficient efficacy and dissatisfaction they are often discontinued.71,104 Using medication such as triptans and NSAIDS may lead to chronic migraine.105 A large-scale study based on US health insurance claims database during 2003-2005 on 4634 patients who started migraine prophylaxis with antidepressants, antiepileptic drugs, or beta-blockers shows that they were no longer taking these medications at 6 months.106

A survey of 190 patients with episodic (n=59) and chronic (n=131) migraine with and without aura after 3 months following single-pulse TMS shows 62% of the patients reported pain relief and over 52%-55% had reduction of associated symptoms such as nausea, photophobia and phonophobia. After 3 months, the mean headache days in episodic migraine reduced from 12 to 9 days and for the chronic migraine patients from 24 to 16 days.107

A recent study in rats and cats shows that single-pulse TMS is able to inhibit both mechanical and chemically-induced cortical spreading depression and reduced the firing of third-order neurons (thalamocortical) but not 2nd-order neurons of the trigemino-cerebral complex.102

All together, these studies show the efficacy of single-pulse TMS in the non-pharmacological treatment of migraine but more studies on the aura symptoms and perhaps effect of TMS on cerebral blood flow might be helpful, however, the procedure seems to be safe and tolerable.105

**DISCUSSION**

Migraine is one of the most prevalent neurological disorders that is characterized by headache, gastrointestinal problems and sensory dysfunction. Because of its multifactorial etiology, migraine is very difficult to treat. Migraine therapy is based on the acute and preventive treatments. There are several pharmacological and non-pharmacological treatments of migraine currently available in clinical practice. Many of the pharmacologic treatment of migraine have side effects and contraindications and with the insufficient efficacy and dissatisfaction they are often discontinued.71,104 Using medication such as triptans and NSAIDS may lead to chronic migraine.105 A large-scale study based on US health insurance claims database during 2003-2005 on 4634 patients who started migraine prophylaxis with antidepressants, antiepileptic drugs, or beta-blockers shows that they were no longer taking these medications at 6 months.106 Therefore, alternative and additional treatment options are necessary for the unmet treatment of migraine. This review was aimed to update us on the new advances in the treatment of migraine through neuromodulation. A number of clinical studies in recent years initiated the acute and preventive treatment of migraine specially the chronic medically intractable headaches using novel invasive and non-invasive neurostimulation of the peripheral and central nervous system.

The invasive devices are implanted subcutaneously or through other surgeries and are powered by implantable batteries or controlled wirelessly, while the non-invasive devices are applied on the skin close to the nerve and can be self-administered by the patient as well.107

The exact mechanism of pain relief by electrical stimulation of nerves is not known very well but it might be due to modulating the release of neurotransmitters including neuropeptides in the CNS and closing the gate of pain and also the brain areas involved in pain processing.50,51

Other studies suggest a central control for pain following such stimulations as seen in VNS.78-80 studies and ONS in cluster headache (CH) patients. Using metabolic neuroimaging by PET, several areas of brain of CH patients showed hypermetabolism.108 Increased hypermetabolism seen by uptake of [18F] fluorodeoxyglucose (FDG) was detected on PET in the ipsilateral hypothalamus, midbrain, and ipsilateral lower pons of CH patients.109 All hypermetabolic areas were normalized following ONS except the hypothalamus which was proposed to be possibly responsible for the autonomic attacks persistence despite pain relief.108 In the responders of ONS in that study, the perigenual anterior cingulate cortex was hyperactive compared to non-responders, indicating the importance of this endogenous opioid system in the brain in modulating pain.108

Moreover, ONS and transcuta-neous electrical stimulation might relieve pain through neuro-modulatory effects in the limbic system and cortical pain control areas, see reference for review.71

Electrical stimulation of the greater occipital nerve was one of the invasive methods discussed in this review. Two major studies were mentioned: The ONSTIM feasibility study.55 Occipital nerve stimulation (ONS) was delivered by means of a pulse generator device that was surgically implanted subcutaneously superficial to the fascia and muscle layer of the back of the neck at the C1 level.55 Hundred and ten patients with chronic migraine participated in the ONSTIM feasibility study. Seventy-five of them were the treated (adjustable stimulated) group. The number of 3-month responders with 50% or more reduction in the number of headache days per month was at 39% in the adjustable stimulated group compared to 6% in the preset (control) stimulated group.

The other large-scale study discussed in this review used ONS on 105 chronic migraine patients and 52 with sham-stimulation. That study showed only a significant difference in the percentage of patients who had 30% decrease in the mean daily visual analog scale scores by 12 weeks (pain reduction) following the stimulation.56 The primary end point in that study was the difference in the percentage of responders that achieved ≥50% reduction in mean daily visual analog scale scores by 12 weeks following the procedure.56

These studies show the efficacy of ONS in treating some chronic migraine patients although the majority of the patients may not have fully benefited from the ONS. Some of the side effects such as paresthesia or infection, other surgery-relat-
ed complications, electrode migration, and battery depletion and replacement, and implant site pain can be seen in the invasive nerve stimulated patients.55,56,71 Nevertheless, more ONS studies on selected patients with more uniform results may be necessary for its recommendation3 which may also help finding more optimal procedural protocols and guidelines.

A number of reasons might contribute to the difference in the responses among patients. These may include the diversity in the etiology of migraine and the different trigger points compared to the level(s) of modulation. Usually these stimulations lead to neuronal modulation at the first central synapses in the spinal cord or trigeminal nucleus and may be confined to a small area in that level and higher CNS areas. If the trigger point for the migraine lies outside the peripheral and/or central territory of the occipital or other stimulated nerves, the modulatory effect of stimulation may not reach the trigger area of the central nervous system. Other reasons might be the peripheral and central sensitizations that may not be affected by such stimulations due to the involvement of multiple signaling molecules.109 Although, procedural and technical errors or surgical complications in general can also contribute to different outcomes but these are usually recognized by the investigators conducting the study.

The other invasive method mentioned in this review was the electrical stimulation of the sphenopalatine ganglion (SPG) for the treatment of acute migraine.

The mechanisms of pain relief following SPG stimulation might possibly be due to interruption of postganglionic parasympathetic outflow and modulation of sensory processing in the caudal trigeminal nucleus.60

In one study mentioned here electrical stimulation of SPG for ≤60 minutes in 10 patients with refractory migraine alleviated the pain in 50% of the patients.65 Currently, there is insufficient data on the efficacy, long-term effect and side effects of SPG stimulation in the treatment of acute migraine. However, sphenopalatine ganglion and its innervation and function is extremely important and relevant for migraine and cluster headache studies and more research including the clinical trials mentioned above in this review will add more to our understanding of the pathomechanism of migraine.

Other neuromodulation/stimulation methods applied for the acute and preventive treatment of migraine with some shown efficacy that were discussed here include the non-invasive electrical stimulation procedures such as vagal nerve stimulation,87,92 the transcutaneous electrical stimulation of supraorbital nerve (TESoSN) and single-pulse transcranial magnetic stimulation.

Some afferent vagal nerve fibers project to the brain stem trigeminal nucleus.110 The mechanism of pain relief following electrical stimulation of the vagus nerve might be due to vagal afferent being able to modulate trigeminovascular pain in the brain stem. Continuous electrical stimulation of vagus nerve in rats modulates trigeminovascular nociception possibly due to decrease in neurotransmitters such as glutamate.111 Electrical stimulation of cardiopulmonary vagal afferent in anesthetized rats modulates nociception in the trigeminal and trigeminothalamic neurons in response to painful orofacial stimulation.112,113 Therefore, electrical stimulation of the vagus nerve has some promising results and more clinical trials should add more to our current understanding of neurostimulation method in the treatment of migraine.

The TESoSN has some moderate effects in the acute and preventive treatment of migraine. One set back with the current technology might be the necessity for its continuous daily use for several minutes continued for several weeks or months to treat migraine.

Table 1 is a brief review of major studies (and their results) that used nerve stimulation to treat migraine in the last couple of years.

CONCLUSION

Although a number of medications are available for the acute and preventive treatment of migraine, neurostimulation techniques have also been used in the treatment of medically intractable headaches in clinical studies in recent years.

Their ability to influence brain network interactions is advancing their applicability.

Among these, electrical stimulation of greater occipital nerve or sphenopalatine ganglion are the invasive ones and the non-invasive procedures include the vagal nerve stimulation, the supraorbital nerve stimulation or the single-pulse transcranial magnetic stimulation.

These recent advances in the management of migraine show some degrees of success. Vagal nerve stimulation is promising and because it is also used in the treatment of other conditions such as epilepsy, advances in this field can help treatment of headaches and other disorders as well as understanding of the mechanism of pain relief. Occipital nerve stimulation results are diverse, and sphenopalatine ganglion stimulation studies are insufficient but are relevant and interesting in headache research. Therefore, more such neuromodulation/nerve stimulation studies with long-term follow up may be necessary to learn more about their tolerability, convenience, effectiveness and side effects in the acute and preventive treatment of migraine. In addition, these clinical studies will shed light into our understanding of pathomechanism of migraine.

Future direction and research in this field can greatly benefit from the guidelines and Consensus Statement of the
| Neurmodulation procedure                        | Major studies done                                                                                                                                                                                                 | Results                                                                                                                                                                                                 |
|------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Occipital nerve stimulation (ONS)              | - ONSTIM feasibility study: used ONS by means of subcutaneous implantation of a pulse generator device for preventive treatment of chronic migraine.56  - 75 out of 110 eligible patients were assigned to treatment group.101  - Another large-scale study used ONS to chronic migraine patients (105 patients with active stimulation and 52 with sham stimulation).101  - The criteria for responders were those patients that achieved ≥50% reduction in mean daily visual analog scale scores by 12 weeks following the procedure.101  - Another study used ONS on 53 patients with chronic migraine (CM) and some within this group suffering from other associated chronic headache phenotypes in addition to CM.27                                                                 | - The treated group (adjustable stimulation group) showed 39% 3-month responders but the control group (preset stimulation or medical management) had 6% and 0% 3-month responder rates.101  - There was a significant difference in the percentage of patients that achieved 30% but not 50% pain reduction. There was also reduction of headache days and other associated symptoms in active stimulated group.101  - After an average of 42 month follow up, there was a 45.3% response rate in the whole cohort defined as >30% reduction in moderate to severe headache days per month. The overall mean subjective patient estimate of improvement was 37%.17                                                                  |
| Pterygopalatine (Sphenopalatine) ganglion stimulation | - One clinical study used electrical stimulation of SPG for ≤60 minutes in 10 patients suffering from refractory migraine.14  - A few other studies are in clinical trials at the moment.                                                                                                                                                                                                 | - The pain was alleviated in only half of the patients although the failure might have been due to technical problems.101                                                                                                                                 |
| Transcutaneous electrical stimulation of supraorbital nerve (TESoSN) | - One investigation in five Belgian tertiary headache clinics used TESoSN in 67 patients for the prevention of migraine. They used a new stimulator called “Cefaly” for 20 min/day for 3 months.70  - EVENT study: 59 patients with chronic migraine took part in this study. 30 patients with nVNS and 29 had sham treatment. Patients had a one month baseline phase and were randomized subsequently to nVNS or sham treatment for 2 months before receiving open-label nVNS.84  - PREVA study: 48 patients in received adjunctive nVNS plus standard of care (SoC) and 49 control patients only with the SoC alone for prophylactic treatment of cluster headache.12                                                                 | - Mean migraine days decreased significantly from 6.94 to 4.68 in the verum stimulated group but almost no difference in the sham stimulated group. The 50% responder rate was significantly higher (38.1%) in verum stimulated versus sham stimulated group (12.1%).55  - After 3 month following TMS 62% had pain relief. Pain free status at 24 hours and 48 hours post-treatment was still significantly higher in the TMS group compared to 22% control group.91  - The pain-free response after 2 hours was 39% in the TMS group compared to 22% control group.101  - Pain was significantly reduced (≥50% reduction in headache days)101  - It improved the headache impact test and disability assessment test.101  - Pain free status at 24 hours and 48 hours post-treatment was still significantly higher in the TMS group.101  - Pain free status at 24 hours and 48 hours post-treatment was still significantly higher in the TMS group.101  - The ≥50% response rate was higher (40%) in the nVNS plus SoC group compared to 8.3% in the SoC alone treated control group.50                                                                                                                                 |
| Non-invasive vagal nerve stimulation (nVNS)     | - VNS was applied on 36 patients with chronic migraine and 14 suffering from high frequency episodic migraine (HFEM).68  - 40 patients with chronic migraine had electrical stimulation of the auricular branch of the vagus nerve by means of a battery driven handheld stimulator to the sensory areas of left ear at 1 Hz for 4 hours per day for 3 months.89  - EVENT study: 59 patients with chronic migraine took part in this study. 30 patients with nVNS and 29 had sham treatment. Patients had a one month baseline phase and were randomized subsequently to nVNS or sham treatment for 2 months before receiving open-label nVNS.84  - PREVA study: 48 patients in received adjunctive nVNS plus standard of care (SoC) and 49 control patients only with the SoC alone for prophylactic treatment of cluster headache.12                                                                 | - 56.3% of the patients had pain reduction (≥50% reduction in visual analog scale “VAS” score) at 1 hour and 64.6% at 2 hour.88  - Of these patients, 35.4% and 39.6% reached a pain-free (VAS: 0) state at 1 and 2 hours respectively.88  - Pain was significantly reduced (≥50% reduction in headache days)89  - It improved the headache impact test and disability assessment test.89  - Mean reduction in the number of headache days was 1.4 in the nVNS versus 0.2 day in the sham-treatment group and the difference was not significant.91  - The ≥50% response rate was higher (40%) in the nVNS plus SoC group compared to 8.3% in the SoC alone treated control group.50                                                                                                                                 |
| Transcranial magnetic stimulation (TMS)         | - One study with 2 groups of migraine patients with aura used stimulation (sTMS) n=82 on one group and sham stimulation on control group, n=82.101  - Another investigation studies 190 patients with episodic (n=69) and chronic (n=131) migraine with and without aura using single-pulse TMS.100                                                                 | - The pain-free response after 2 hours was 39% in the sTMS group compared to 22% control group.101  - Pain free status at 24 hours and 48 hours post-treatment was still significantly higher in the sTMS group.101  - After 3 month following TMS 62% had pain relief.104  - 52%-55% had reduction of associated symptoms such as nausea, photophobia and phonophobia.100  - Mean headache days in episodic migraine reduced from 12 to 9 days and for the chronic migraine patients from 24 to 16 days.101                                                                                                                                 |

Table 1: A brief review of the major clinical studies done for the treatment of migraine using electrical stimulation of various peripheral nerves/neurons or cranial neurons.

2013 European Headache Federation for clinical use of neurmodulation in headache.14

ACKNOWLEDGMENTS

This work has been supported by internal funding by the Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.
REFERENCES

1. Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. *Eur J Neurol*. 2009; 16: 968-981. doi: 10.1111/j.1468-1331.2009.02748.x

2. Samsam M. Drugs against calcitonin gene-related peptide and its receptor used in the treatment of migraine: What are the new progresses? *Neuro Open J*. 2015; 2: 79-91. doi: 10.17140/NOJ-2-117

3. Diener HC, Charles A, Goadsby PJ, Holle D. New therapeautic approaches for the prevention and treatment of migraine. *Lancet Neurol*. 2015; 14(10): 1010-1022. doi: 10.1016/S1474-4422(15)00198-2

4. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. *Nat Med*. 1995; 1: 658-660. doi: 10.1038/nm0795-658

5. Cohen AS, Goadsby PJ. Functional neuroimaging of primary headache disorders. *Expert Rev Neurother*. 2006; 6: 1159-1171. doi: 10.1586/14737175.6.8.1159

6. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. *Trends Mol Med*. 2007; 13: 39-44. doi: 10.1016/j.tomm.2006.11.005

7. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brain-stem mechanisms in migraine. *Nat Rev Neurosci*. 2011; 12: 570-584. doi: 10.1038/nrn3057

8. Samsam M. Central nervous system acting drugs in treatment of migraine headache. *Cent Nerv Syst Agents Med Chem*. 2012; 12: 158-172. doi: 10.2174/187152412802430147

9. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. *Brain*. 1994; 117 (Pt 1): 199-210. doi: 10.1093/brain/117.1.199

10. Tfelt-Hansen PC. History of migraine with aura and cortical spreading depression from 1941 and onwards. *cephalalgia*. 2010; 30(7): 780-92. doi: 10.1111/j.1468-2982.2009.02015.x

11. Lauritzen M, Strong AJ. ‘Spreading depression of Leão’ and its emerging relevance to acute brain injury in humans. *J Cereb Blood Flow Metab*. 2016; pii: 0271678X16657092. doi: 10.1177/0271678X16657092

12. Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. *Cell*. 1996; 87: 543-552. doi: 10.1016/S0092-8674(00)81373-2

13. De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. *Nat Genet*. 2003; 33: 192-196. doi: 10.1038/ng1081

14. Vanmolkot KR, Kors EE, Hottenga JJ, et al. Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. *Ann Neurol*. 2003; 54: 360-366. doi: 10.1002/ana.10674

15. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. *Lancet*. 2005; 366: 371-377. doi: 10.1016/S0140-6736(05)66786-4

16. Kors EE, Vanmolkot KR, Haan J, et al. Recent findings in headache genetics. *Curr Opin Neurol*. 2004; 17: 283-288. Web site. http://journals.lww.com/co-neurology/Abstract/2004/06000/Recent_findings_in_headache_genetics.8.aspx. Accessed December 27, 2016.

17. van den Maagdenberg AM, Pietrobon D, Pizzorusso T, et al. A CaCna1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. *Neuron*. 2004; 41: 701-710. doi: 10.1016/S0896-6273(04)00085-6

18. Olsen J. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. *Cephalalgia*. 2004; 241: 9-160.

19. Ferrari MD, Klever RR, Terwindt GM, Ayata C, van den Maagdenberg AM. Migraine pathophysiology: lessons from mouse models and human genetics. *Lancet Neurol*. 2015; 14(1): 65-80. doi: 10.1016/S1474-4422(14)70220-0

20. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). *Cephalalgia*. 2013; 33(9): 629-808.

21. Gallai V, Sarchielli P, Floridi A, et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. *Cephalalgia*. 1995; 15(5): 384-390. doi: 10.1046/j.1468-2982.1995.1505384.x

22. Olesen J, Diener HC, Hutsedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. *N Engl J Med*. 2004; 350(11): 1104-1110. doi: 10.1056/NEJMoa030505

23. Iovino M, Feifel U, Yong CL, Wolters JM, Wallenstein G. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers. *Cephalalgia*. 2004; 24: 645-656. doi: 10.1111/j.1468-2982.2004.00726.x
24. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral agonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. *Lancet.* 2008; 372: 2115-2123. doi: 10.1016/S0140-6736(08)61626-8

25. Ho TW, Mannix LK, Fan X, et al. MK-0974 Protocol 004 study group. Collaborators (20), Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. *Neurology.* 2008; 70: 1304-1312. doi: 10.1212/01.WNL.0b013e3181b87942

26. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. *Neurology.* 2009; 73: 970-977. doi: 10.1212/01.WNL.0b013e3181b87942

27. Salvatore CA, Moore EL, Calamari A, et al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. *J Pharmacol Exp Ther.* 2010; 333: 152-160. doi: 10.1124/jpet.109.163816

28. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. *Cephalalgia.* 2011; 31: 712-722. doi: 10.1177/0333102411398399

29. Diener HC, Barbanti P, Dahlöff C, et al. BI44370TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study. *Cephalalgia.* 2011; 31: 573-84. doi: 10.1177/0333102410388435

30. Leahy DK, Fan Y, Desai LV, et al. Efficient and scalable enantioselective synthesis of a CGRP antagonist. *Org Lett.* 2012; 14: 4938-4941. doi: 10.1021/ol302262q

31. Luo G, Chen L, Conway CM, et al. Discovery of BMS-846372, a Potent and Orally Active Human CGRP Receptor Antagonist for the Treatment of Migraine. *ACS Med Chem Lett.* 2012; 3: 337-341. doi: 10.1021/ml300021s

32. Voss T, Lipton RB, Dodick DW, et al. A phase Ib randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. *Cephalalgia.* 2016; 36: 887-898. doi: 10.1177/0333102416653233

33. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomized, double-blind, placebo-controlled study. *Lancet Neurol.* 2014; 13: 885-892. doi: 10.1016/S1474-4422(14)70128-0

34. Dodick DW, Goadsby PJ, Silberstein SD, et al. ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: A randomized, double-blind, placebo-controlled, exploratory phase 2 trial. *Lancet Neurol.* 2014; 13(11): 1100-1107. doi: 10.1016/S1474-4422(14)70209-1

35. Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program. *Cephalalgia.* 2013; 34(7): 483-492. doi: 10.1177/033310241351777

36. Bigal ME, Dodick DW, Krymchantowski AV, et al. TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points. *Neurology.* 2016; 87(1): 41-88. doi: 10.1212/WNL.0000000000002801

37. Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. *Br J Clin Pharmacol.* 2015; 79(6): 886-895. doi: 10.1111/bcp.12591

38. Ferrari MD, Färkkilä M, Reuter U, et al. European COL-144 Investigators. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan--a randomized proof-of-concept trial. *Cephalalgia.* 2010; 30: 1170-1178. doi: 10.1177/0333102410375512

39. Nelson DL, Phebus LA, Johnson KW, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. *Cephalalgia.* 2010; 30: 1159-1169. doi: 10.1177/0333102410370873

40. Färkkilä M, Diener HC, Géraud G, et al. COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. *Lancet Neurol.* 2012; 11(5): 405-413. doi: 10.1016/S1474-4422(12)70047-9

41. Hoffmann J, Goadsby PJ. Emerging targets in migraine. *CNS Drugs.* 2014; 28: 11-17. doi: 10.1007/s40263-013-0126-2

42. Karsan N, Goadsby PJ. CGRP mechanism antagonists and migraine management. *Curr Neurol Neurosci Rep.* 2015; 15(5): 25. doi: 10.1007/s11910-015-0547-z

43. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migraine therapy. *Springerplus.* 2016; 5: 637. doi: 10.1186/s40064-016-2211-8

44. Starling AJ, Vargas BB. A narrative review of evidence-based preventive options for chronic migraine. *Curr Pain Headache Rep.* 2015; 19(10):49. doi: 10.1007/s11916-015-0521-0

45. Picaza JA, Cannon BW, Hunter SE, Boyd AS, Guma J, Maur-
46. Picaza JA, Cannon BW, Hunter SE, Boyd AS, Gunn J, Maurer D. Pain suppression by peripheral nerve stimulation. Part II. Observations with implanted devices. Surg Neurol. 1975; 4(1): 115-126.

47. Picaza JA, Hunter SE, Cannon BW. Pain suppression by peripheral nerve stimulation. Chronic effects of implanted devices. Appl Neurophysiol. 1977-1978; 40(2-4): 223-234. doi: 10.1159/000102446

48. Lou L. Uncommon areas of electrical stimulation for pain relief. Curr Rev Pain. 2000; 4(5): 407-412. doi: 10.1007/s11916-000-0025-3

49. Van Calenbergh F, Gybels J, Van Laere K, et al. Long term clinical outcome of peripheral nerve stimulation in patients with chronic peripheral neuropathic pain. Surg Neurol. 2009; 72(4): 330-335. doi: 10.1016/j.surneu.2009.03.006

50. Stanton-Hicks M, Salamon J. Stimulation of the central and peripheral nervous system for the control of pain. J Clin Neurophysiol. 1997; 14(1): 46-62.

51. Stojanovic MP. Stimulation methods for neuropathic pain control. Curr Pain Headache Rep. 2001; 5(2): 130-137. doi: 10.1007/s11916-001-0081-3

52. Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: A synthesis of the central structures involved in migraine. Headache. 1991; 31(6): 365-371.

53. Weiner RL, Reed KL. Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation. 1999; 2(3): 217-221. doi: 10.1046/j.1525-1403.1999.00217.x

54. Nörenberg E, Winkelmüller W. The epifacial electric stimulation of the occipital nerve in cases of therapy-resistant occipital neuralgia. Neuromodulation. 2009; 12(5): 399-412. doi: 10.1111/j.1526-4610.2009.01451.x

55. Piagkou M, Demesticha T, Troupis T, et al. The pterygopalatine ganglion and its role in various pain syndromes: From anatomy to clinical practice. Pain Pract. 2012; 12(5): 399-412. doi: 10.1111/j.1533-2500.2011.00507.x

56. Silberstein SD, Dodick DW, Saper J, et al. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012; 32(16): 1165-1179. doi: 10.1177/033102412462642

57. Miller S, Watkins L, Matharu M. Long-term outcomes of occipital nerve stimulation for chronic migraine: A cohort of 53 patients. J Headache Pain. 2016; 17(1): 68. doi: 10.1186/s10194-016-0659-0

58. Clark SW, Venkatesan L, Boorman D, et al. Comparison of efficacy of tonic and burst occipital nerve stimulation in treating trigeminal allodynia: Chronic Result. Neurosurgery. 2016; 63(Suppl 1): 175. doi: 10.1227/01.neu.0000489758.97532.6a

59. Slotty PJ, Bara G, Kowitz L, et al. Occipital nerve stimulation for chronic migraine: A randomized trial on subthreshold stimulation. Cephalalgia. 2015; 35(1): 73-78. doi: 10.1177/0333102414534082

60. Khan S, Schoenen J, Ashina M. Sphenopalatine ganglion neurenomodulation in migraine: What is the rationale? Cephalalgia. 2014; 34(5): 382-391. doi: 10.1177/0333102413512032

61. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ, ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011; 31(3): 271-285. doi: 10.1177/033102410381142

62. Klein RN, Burk DT, Chase PF. Anatomically and physiologically based guidelines for use of the sphenopalatine ganglion block versus the stellate ganglion block to reduce atypical facial pain. Cranio. 2001; 19(1): 48-55. doi: 10.1080/08869634.2001.11746151

63. Schoenen J. Sphenopalatine ganglion stimulation in neurovascular headaches. Prog Neurol Surg. 2015; 29: 106-116. doi: 10.1159/000434661

64. Fox EJ, Melzack R. Transcutaneous electrical stimulation and acupuncture: Comparison of treatment for low-back pain. Pain. 1976; 2(2): 141-148. doi: 10.1016/0304-3959(76)90109-3

65. Tepper SJ, Rezai A, Narouze S, Steiner C, Mohajer P, Ansarina M. Acute treatment of intractable migraine with sphenopalatine ganglion electrical stimulation. Headache. 2009; 49(7): 983-989. doi: 10.1111/j.1526-4610.2009.01451.x

66. Cook IA, Abrams M, Leuchter AF. Trigeminal nerve stimulation for comorbid posttraumatic stress disorder and major depressive disorder. Neuromodulation. 2016; 19(3): 299-305. doi: 10.1111/ner.12399
69. Schoenen J, Roberta B, Magis D, Coppola G. Noninvasive neurostimulation methods for migraine therapy: The available evidence. Cephalalgia. 2016; pii: 0333102416636022. doi: 10.1177/0333102416636022

70. Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial. Neurology. 2013; 80(8): 697-704. doi: 10.1212/WNL.0b013e3182825055

71. Riederer F, Penning S, Schoenen J. Transcutaneous supraorbital nerve stimulation (t-SNS) with the Cefaly® device for migraine prevention: A Review of the available data. Pain Ther. 2015; 4(2): 135-147. doi: 10.1007/s40122-015-0039-5

72. Russo A, Tessitore A, Conte F, et al. Transcutaneous supraorbital neurostimulation in "de novo" patients with migraine without aura: The first Italian experience. J Headache Pain. 2015; 16: 69. doi: 10.1186/s10194-015-0551-3

73. Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly® device in headache treatment: A survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013; 14: 95. doi: 10.1186/1129-2377-14-95

74. Magis D, D’Ostilio K, Thibaut A, et al. Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia. 1998; 39(9): 983-990.

75. Vonck K, Van Laere K, Dedeurwaerdere S, et al. The mechanism of action of vagus nerve stimulation for refractory epilepsy: The current status. J Clin Neurophysiol. 2001; 18(5): 394-401.

76. Vonck K, Poelmans G, Dedeurwaerdere S, et al. The mechanism of action of vagus nerve stimulation for refractory epilepsy: The current status. J Clin Neurophysiol. 2001; 18(5): 394-401.

77. Bohnhöfer DE, Lomarev MP, Denslow S, Nahas Z, Shastri A, George MS. Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI. Invest Radiol. 2001; 36(8): 470-479.

78. Ko D, Heck C, Grafton S, et al. Vagus nerve stimulation activates central nervous system structural changes in epileptic patients during PET H2(15)O blood flow imaging. Neurosurgery. 1996; 39(2): 426-430.

79. Henry TR, Bakay RA, Votaw JR, et al. Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy: I. Acute effects at high and low levels of stimulation. Epilepsia. 1998; 39(9): 983-990.

80. Narayanan JT, Watts R, Haddad N, Labar DR, Li PM, Filippi CG. Cerebral activation during vagus nerve stimulation: A functional MR study. Epilepsia. 2002; 43(12): 1509-1514.

81. Hord ED, Evans MS, Muedd D, Adamolekun B, Naritoku DK. The effect of vagus nerve stimulation on migraines. J Pain. 2003; 4(9): 530-534. doi: 10.1016/j.jpain.2003.08.001

82. Mauskop A. Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia. 2005; 25(2): 82-86. doi: 10.1111/j.1468-2982.2005.00611.x

83. Cecchini AP, Mea E, Tullo V, et al. Vagus nerve stimulation in drug-resistant daily chronic migraine with depression: Preliminary data. Neurol Sci. 2009; 30(1): S101-S104. doi: 10.1007/s10072-009-0073-3

84. Mosquera AJ, López-Manzanares L, Canneti B, et al. Vagus nerve stimulation in patients with migraine. Rev Neurol. 2013; 57(2): 57-63.

85. Ness TJ, Fillingim RB, Backensto EM, Faught E. Low intensity vagal nerve stimulation lowers human thermal pain thresholds. Pain. 2000; 86(1-2): 81-85.

86. Chen SP, Ay I, de Morais AL, et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain. 2016; 157(4): 797-805. doi: 10.1097/j.pain.0000000000002918

87. Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive vagus nerve stimulation on acute migraine: An open-label pilot study. Cephalalgia. 2014; 34(12): 986-993. doi: 10.1177/0333102414524494

88. Barbanti P, Grazzi L, Egeo G, et al. Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: An open-label study. J Headache Pain. 2015; 16: 61. doi: 10.1186/s10194-015-0542-4

89. Straube A, Ellrich J, Eren O, Blum B, Ruchcwey H. Treatment of chronic migraine with transcutaneous stimulation of the auricular branch of the vagal nerve (auricular t-VNS): A randomized, monocentric clinical trial. J Headache Pain. 2015; 16: 543. doi: 10.1186/s10194-015-0543-3

90. Kinfe TM, Pintea B, Muhammad S, et al. Cervical noninvasive vagus nerve stimulation (nVNS) for preventive and acute treatment of episodic and chronic migraine and migraine-associated sleep disturbance: A prospective observational cohort study. J Headache Pain. 2015; 16: 101. doi: 10.1186/s10194-015-0582-9

91. Silberstein SD, Calhoun AH, Lipton RB, et al. EVENT Study Group. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016; 87(5): 529-538. doi: 10.1212/WNL.0000000000002918
92. Gaul C, Diener HC, Silver N, et al. PREVA Study Group. Non-invasive vagus nerve stimulation for PREvention and Acute treatment of chronic cluster headache (PREVA): A randomised controlled study. *Cephalalgia*. 2016; 36(6): 534-546. doi: 10.1177/0333102415607070

93. Knyhár-Csillik E, Tajti J, Samsam M, Sáry G, Slezák S, Vécsei L. Effect of a serotonin agonist (sumatriptan) on the pepsidergic innervation of the rat cerebral dura mater and on the expression of c-fos in the caudal trigeminal nucleus in an experimental migraine model. *J Neurosci Res*. 1997; 48(5): 449-464.

94. Samsam M, Coveñas R, Ahangari R, Vajeya J, Narváez JA, Tramu G. Simultaneous depletion of neurokinin A, substance P and calcitonin gene-related peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. *Pain*. 2000; 84(2-3): 389-395.

95. Samsam M, Coveñas R, Csillik B, et al. Depletion of substance P, neurokinin A and calcitonin gene-related peptide from the contralateral and ipsilateral caudal trigeminal nucleus following unilateral electrical stimulation of the trigeminal ganglion; A possible neurophysiological and neuroanatomical link to generalized head pain. *J Chem Neuroanat*. 2001; 21(2): 161-169. doi: 10.1016/S0891-0618(01)00088-6

96. Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. *Proc Natl Acad Sci U S A*. 2016; 113(29): 8284-8289. doi: 10.1073/pnas.1605635113

97. Rössler KM, Hess CW, Schmid UD. Investigation of facial motor pathways by electrical and magnetic stimulation: Sites and mechanisms of excitation. *J Neurol Neurosurg Psychiatry*. 1987; 52(10): 1149-1156.

98. Mills KR, Murray NM, Hess CW. Magnetic and electrical transcranial brain stimulation: Physiological mechanisms and clinical applications. *Neurosurgery*. 1987; 20(1): 164-168.

99. Lo YL. Headache: Migraine, magnetic stimulation and cortical excitability. *Nat Rev Neurol*. 2010; 6(8): 425-427. doi: 10.1038/nrneurol.2010.109

100. Bhola R, Kinsella E, Giffin N, et al. Single-pulsetranscranial magnetic stimulation (sTMS) for the acute treatment of migraine: Evaluation of outcome data for the UK post market pilot program. *J Headache Pain*. 2015; 16: 535. doi: 10.1186/s10194-015-0535-3

101. Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulstranscranial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallel-group, sham-controlled trial. *Lancet Neurol*. 2010; 9(4): 373-380. doi: 10.1016/S1474-4422(10)70054-5

102. Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ. Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. *Brain*. 2016; 139(Pt 7): 2002-2014. doi: 10.1093/brain/aww118

103. Dodick DW, Schembri CT, Helmuth M, Aurora SK. Transcranial magnetic stimulation for migraine: A safety review. *Headache*. 2010; 50(7): 1153-1163. doi: 10.1111/j.1526-4610.2010.01697.x

104. Lipton RB, Buse DC, Serrano D, Holland S, Reed ML. Examination of unmet treatment needs among persons with episodic migraine: Results of the American Migraine Prevalence and Prevention (AMPP) Study. *Headache*. 2013; 53(8): 1300-1311. doi: 10.1111/head.12154

105. Lipton RB, Serrano D, Nicholson RA, Buse DC, Runken MC, Reed ML. Impact of NSAID and Triptan use on developing chronic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. *Headache*. 2013; 53(10): 1548-1563. doi: 10.1111/head.12201

106. Berger A, Bloudek LM, Varon SF, Oster G. Adherence with migraine prophylaxis in clinical practice. *Pain Pract*. 2012; 12(7): 541-549. doi: 10.1111/j.1533-2500.2012.00530.x

107. Schuster NM, Rapoport AM. New strategies for the treatment and prevention of primary headache disorders. *Nat Rev Neurol*. 2016; 12(11): 635-650. doi: 10.1038/nrneurol.2016.143

108. Magis D, Bruno MA, Fumal A, et al. Central modulation in cluster headache patients treated with occipital nerve stimulation: An FDG-PET study. *BMC Neurol*. 2011; 11: 25. doi: 10.1186/1471-2377-11-25

109. Samsam M, Coveñas R, Ahangari R, Yajeya J. Neuropeptides and other chemical mediators, and the role of anti-inflammatory drugs in primary headaches. *Annals of Medicine*. 2010; 3: 170-188. doi: 10.2174/1871523011009030170

110. Contreras RJ, Beckstead RM, Norgren R. The central projections of the trigeminal, facial, glossopharyngeal and vagus nerves: An autoradiographic study in the rat. *J Auton Nerv Syst*. 1992; 6(3): 303-322.

111. Lyubashina OA, Sokolov AY, Panteleev SS. Vagal afferent modulation of spinal trigeminal neuronal responses to dural electrical stimulation in rats. *Neuroscience*. 2012; 222: 29-37. doi: 10.1016/j.neuroscience.2012.07.011

112. Bossut DF, Maixner W. Effects of cardiac vagal afferent electrostimulation on the responses of trigeminal and trigeminothalamic neurons to noxious orofacial stimulation. *Pain*. 1996; 65(1): 101-119.

113. Puledda F, Goadsby PJ. Current approaches to neuromodulation in primary headaches: Focus on vagal nerve and sphenopalatine ganglion stimulation. *Curr Pain Headache Rep*. 2016;
114. Martelletti P, Jensen RH, Antal A, et al. European Headache Federation. Neuromodulation of chronic headaches: Position statement from the European Headache Federation. *J Headache Pain.* 2013; 14: 86. doi: 10.1186/1129-2377-14-86